Private Market View

Eikon Therapeutics (NAS: EIKN)

Millbrae, CA · Founded 2019 · Publicly Held

Last price · $/share
—
Implied valuation
$971.7M
Total raised
$1.5B
Last round
—

Key facts

  • Eikon Therapeutics (NAS: EIKN)’s last known valuation is $971.7M (Feb 2026).
  • It has raised $1.5B; the latest was IPO ($381.2M) in Feb 2026.
  • Notable investors include General Catalyst, Lux Capital, Alexandria Venture Investments, StepStone Group, AME Cloud Ventures — 22 tracked in total.
  • 1 institutional filer reports fund marks on Eikon Therapeutics (NAS: EIKN) across 2 filings.
  • Status: Publicly Held.
Free account
See the evidence behind this price
  • ·The complete investor list — 22 names
  • ·Watchlist + deal alerts for Eikon Therapeutics (NAS: EIKN)
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Eikon Therapeutics (NAS: EIKN) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Eikon Therapeutics (NAS: EIKN)

Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.

Sector
Healthcare
HQ
Millbrae, CA, United States
Founded
2019
Employees
384
Ownership
Publicly Held
PA Mark — not yet priced

Eikon Therapeutics (NAS: EIKN) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Eikon Therapeutics (NAS: EIKN) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

1 filers · latest May 2026

1 SEC-registered fund reported 2 fair-value marks on Eikon Therapeutics (NAS: EIKN) between Feb 2026 and May 2026. Filer-level marks and implied $/share are available to Pro members.

Unlock 2 fund marks